DOPATREE
Preview
Open in TheBrain
DOPATREE
UNITED STATES GOVERNMENT ORGANIZATIONS / LISTINGS
US FOOD AND DRUG ADMINISTRATION (FDA)
DRUGS AND BIOLOGICS / RELATED / US
US FDA NEW MOLECULAR ENTITY APPROVALS (NME, NEW CHEMICAL ENTITIES, NBE, NEW BIOLOGICAL ENTITIES)
US FDA NEW MOLECULAR ENTITY APPROVALS / LISTINGS / 2021
UMBRALISIB (UKONIQ®-WITHDRAWN 2022)
UMBRALISIB / BRANDS
UKONIQ (UMBRALISIB-WITHDRAWN 2022)
UKONIQ / NEWS
Parents
UKONIQ (UMBRALISIB-WITHDRAWN 2022)
Children
TG THERAPEUTICS. TG THERAPEUTICS ANNOUNCES VOLUNTARY WITHDRAWAL OF THE BLA/SNDA FOR U2 TO TREAT PATIENTS WITH CLL AND SLL. APR 15, 2022.
US FDA. FDA APPROVAL OF LYMPHOMA MEDICINE UKONIQ (UMBRALISIB) IS WITHDRAWN DUE TO SAFETY CONCERNS. JUN 1, 2022.